S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
LON:OXB

Oxford Biomedica Share Forecast, Price & News

GBX 1,360
+4.00 (+0.29%)
(As of 11/29/2021 11:19 AM ET)
Add
Compare
Today's Range
1,342
1,382
50-Day Range
1,350
1,634
52-Week Range
810
1,678
Volume
17,497 shs
Average Volume
148,395 shs
Market Capitalization
£1.17 billion
P/E Ratio
61.54
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive OXB News and Ratings via Email

Sign-up to receive the latest news and ratings for Oxford Biomedica and its competitors with MarketBeat's FREE daily newsletter.


Oxford Biomedica logo

About Oxford Biomedica

Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various diseases in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes. The company's products under development stage include OXB-302 that targets haematological tumours with a CAR-T 5T4; OXB-203, which is in pre-clinical stage for the treatment of wet age-related macular degeneration; OXB-204, a lentiviral-based therapy for the ocular disease Leber's congenital amaurosis variant 10; OXB-103 (ALS) for central nervous system; and OXB-401 for liver indication. Its partnered products in development stage comprise AXO-Lenti-PD that is in a Phase I/II trial preparation for the treatment of Parkinson's disease; SAR 422459, which is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869 that is in Phase I/II trial for the treatment of Usher syndrome 1B. Oxford Biomedica plc has partnerships with Novartis, Bristol Myers Squibb, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations, Santen Pharmaceutical Co Ltd, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Papyrus Therapeutics, Inc. to assess the impact and therapeutic benefit of PYTX-002, a gene replacement therapy to confer cellular pharmacy properties on a CAR-T cell therapy. It has a discovery collaboration with PhoreMost Limited to develop CAR-T cell therapies. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.

Headlines

Oxford Biomedica Share Price (OXB.GB.PL)
June 19, 2021 |  lse.co.uk
Will the Oxford Biomedica share price keep on climbing?
June 15, 2021 |  uk.finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
673
Year Founded
N/A

Sales & Book Value

Annual Sales
£135.00 million
Cash Flow
GBX 73.87 per share
Book Value
GBX 160.60 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
£1.17 billion
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.71 out of 5 stars

Analyst Opinion: 2.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Oxford Biomedica (LON:OXB) Frequently Asked Questions

Is Oxford Biomedica a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oxford Biomedica in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Oxford Biomedica stock.
View analyst ratings for Oxford Biomedica
or view top-rated stocks.

How has Oxford Biomedica's stock price been impacted by COVID-19 (Coronavirus)?

Oxford Biomedica's stock was trading at GBX 525 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, OXB shares have increased by 159.0% and is now trading at GBX 1,360.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for OXB?

4 brokerages have issued 1 year target prices for Oxford Biomedica's shares. Their forecasts range from GBX 1,200 to GBX 2,150. On average, they anticipate Oxford Biomedica's stock price to reach GBX 1,707.50 in the next twelve months. This suggests a possible upside of 25.6% from the stock's current price.
View analysts' price targets for Oxford Biomedica
or view top-rated stocks among Wall Street analysts.

Who are Oxford Biomedica's key executives?

Oxford Biomedica's management team includes the following people:
  • Mr. John Dawson, CEO & Exec. Director (Age 61, Pay $834k)
  • Mr. Stuart Paynter, CFO, Company Sec. & Director (Age 47, Pay $476k)
  • Mr. Nick Page, Chief Operations Officer
  • Dr. James Miskin Ph.D., Chief Technical Officer
  • Dr. Kyriacos Mitrophanous Ph.D., Chief Scientific Officer
  • Ms. Catherine Isted, Head of Corp. Devel. & IR
  • Ms. Natalie Louise Walter, Gen. Counsel
  • Ms. Sarah Macleod, Head of Communications
  • Ms. Helen Stephenson-Ellis, Chief People Officer
  • Dr. Richard Harrop D.Phil. B.Sc., Head of Clinical Analysis

What other stocks do shareholders of Oxford Biomedica own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford Biomedica investors own include EnQuest (ENQ), Petra Diamonds (PDL), Sirius Minerals (SXX), Centamin (CEY), Lloyds Banking Group (LLOY), Oxford Biomedica (OXBDF), Premier Oil (PMO), AFR.L (AFR), Barclays (BARC) and Genel Energy (GENL).

What is Oxford Biomedica's stock symbol?

Oxford Biomedica trades on the London Stock Exchange (LON) under the ticker symbol "OXB."

How do I buy shares of Oxford Biomedica?

Shares of OXB and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Oxford Biomedica's stock price today?

One share of OXB stock can currently be purchased for approximately GBX 1,360.

How much money does Oxford Biomedica make?

Oxford Biomedica has a market capitalization of £1.17 billion and generates £135.00 million in revenue each year.

How many employees does Oxford Biomedica have?

Oxford Biomedica employs 673 workers across the globe.

What is Oxford Biomedica's official website?

The official website for Oxford Biomedica is www.oxfordbiomedica.co.uk.

Where are Oxford Biomedica's headquarters?

How can I contact Oxford Biomedica?

Oxford Biomedica's mailing address is Windrush Court, Transport Way, OXFORD, OX4 6LT, United Kingdom. The biopharmaceutical company can be reached via phone at +44-1865-783000.


This page was last updated on 11/29/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.